Verona Pharma (VRNA)

• Market cap: $3.44B
• 1 day: 1.94%
• 5 days: 0.86%
• 1 month: 8.16%
• 3 months: 40.11%
• 6 months: 186.04%
• Year to date: 123.39%
• 1 year: 153.44%
• 5 years: 846.40%
• 10 years: 211.26%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Employees: 79

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

130% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 20

102% more capital invested

Capital invested by funds: $965M [Q2] → $1.94B (+$979M) [Q3]

57% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 11 (+4) [Q3]

21% more funds holding

Funds holding: 123 [Q2] → 149 (+26) [Q3]

0.73% less ownership

Funds ownership: 11.11% [Q2] → 10.38% (-0.73%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 46

12% less call options, than puts

Call options by funds: $24.3M | Put options by funds: $27.6M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 0% upside
• Avg. target: $49 15% upside
• High target: $64 52% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Tiago Fauth 72% 1-year accuracy 13 / 18 met price target	52% upside $64	Overweight Maintained	5 Nov 2024
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target	0% downside $42	Buy Maintained	5 Nov 2024
Canaccord Genuity Edward Nash 72% 1-year accuracy 13 / 18 met price target	5% upside $44	Buy Maintained	5 Nov 2024
Truist Securities Joon Lee 47% 1-year accuracy 17 / 36 met price target	5% upside $44	Buy Maintained	9 Oct 2024